Skip Navigation
  • The MHH
  • International office
  • Emergency numbers
  • Patients & Visitors
  • Facilities & Departments
    • Facilities & Departments
    • MHH Clinical departments
    • MHH-Institutes
    • Clinical departments and institutes sorted by center
    • Interdisciplinary centers
    • Central facilities
  • Research
    • Research
    • Research foci
      • Research foci
      • COVID-19
    • Core Research Units
      • Core Research Units
      • MeDIC
      • Hannover Unified Biobank (HUB)
      • Lasermikroskopie
      • Research Core Unit Electron Microscopy
    • Academic Career Development
    • Advisory Services
      • Advisory Services
      • DFG
    • Research Infrastructure
    • Dean of Research
    • Good Scientific Practice
      • Good Scientific Practice
      • Commission for Good Scientific Practice
      • Ombuds Office and Ombudsperson
    • Transparency in Research
    • Research Funding, Knowledge & Technology Transfer
      • Research Funding, Knowledge & Technology Transfer
      • Partners & Networks
      • For life scientists
      • For partners & investors
      • For startups and founders
  • Studying at MHH
    • Studying at MHH
    • All degree programs
    • Registrar's Office
      • Registrar's Office
      • Prospective students
      • Students
      • Dates & deadlines
      • Contact
  • Careers
Welcome to the MHH
Searched for 1"'`--. Found 557 results in 3 Millisekunden.

Filter by:

  • All content
  • Common content
  • Ambulances
  • News
  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • »
News

Clinical trial to test new combination therapy against blood cancer

Relevance: 96%
 

ingredients ivosidenib and azacitidine. While the former inhibits a specific gene-modified enzyme called IDH1 that promotes the development of blood cancer cells, the latter prevents cancer cells from growing. [...] two drugs improved survival in people newly diagnosed with AML that had gene alterations in the IDH1 enzyme. However, the standard treatment is currently still either chemotherapy or stem cell transplantation [...] or who, after initial improvement, have subsequently relapsed. They are to be treated with the IDH1 inhibitor ivosidenib in combination with the active substance molidustat. The drug stimulates the production

Page

Publications

Relevance: 95%
 

Benlagha K. Intrinsic factors and CD1d1 but not CD1d2 expression levels control invariant natural killer T cell subset differentiation. Nat Commun. 2023 Dec 1;14(1):7922. doi: 10.1038/s41467-023-43424-7 [...] unique characteristics of peptide-specific PLZF+ innate-like T cells in mice. Nat Commun. 2025 Jun 6;16(1):5274. doi: 10.1038/s41467-025-60617-4. PMID: 40480992; PMCID: PMC12144119. 2024 Hesham D, Mosaab A [...] unveils a potential tumor suppressor role in pediatric choroid plexus carcinoma. Sci Rep. 2024 Sep 12;14(1):21293. doi: 10.1038/s41598-024-71188-7. PMID: 39266576; PMCID: PMC11393135. 2023 Amable L, Ferreira

Page

Projects

Relevance: 95%
 

d; M. Smyth, QIMR Berghofer MRI, Herston, QLD, Australia. 03/1996 – 01/2001 Sachbeihilfen BE 1886/1-1, BE 18861-2 – Function and regulation of expression of the cellular receptor for poliovirus (CD155) [...] Completed Projects of the Bernhardt Group 04/2015 – 10/2018 Sachbeihilfe BE 1886/5-1 - Investigating murine follicular T cells as well as the contribution of the antagonistic CD155 ligands TIGIT and CD226 [...] France; G.G. Loots, Lawrence Livermore Laboratory, CA, USA. 04/2004 – 02/2016 Sachbeihilfen BE 1886/2-1, BE 1886/2-2, BE 1886/2-3 – Functional analysis of the adhesion receptor CD155 and its ligands. Cooperation

Page

Teaching

Relevance: 95%
 

Vorlesung Biophysikalische Chemie (1. Fachsemester, Modul BCM P 04) Übungen Biophysikalische Chemie (1. Fachsemester, Modul BCM P 04) Praktikum Biophysikalische Chemie (1. Fachsemester, Modul BCM P 04) L

Page

[Translate to Englisch:] StrucMed

Relevance: 95%
 

während dieser Zeit für zwei Semester ausgesetzt Optimaler Zeitpunkt: nach dem 1. klinischen Studienjahr (nach dem 6. Semester); die M1 Prüfung muss abgeschlossen sein. Die schriftliche Doktorarbeit sollte a [...] e, Institutsseminare, Kolloquien, Tierkurs, wissenschaftliches Schreiben, Statistik etc. 1 Hauptbetreuer und 1 Kobetreuer (aus einer anderen Abteilung) Bezahlung als studentische Hilfskraft oder mit Stipendium [...] Verantwortlichen und aktuellen Studierenden) Kontakt : Dr. Susanne Kruse, HBRS Büro, Gebäude J4 , Ebene 1, Tel. -9844; Fax. -2611; kruse.susanne@mh-hannover.de Unterstützung : Das StrucMed Programm wird durch

Page

Receptor/ligand interactions

Relevance: 94%
 

inhibitory ligand hPD-L1 (CD274) and pigs lacking functional MHC (SLA, "swine leukocyte antigen") class I were generated. In vitro studies showed that SLA class I-deficient and hPD-L1 tg cells are only partially [...] partially protected from human immune responses. We expect that hPD-L1 positive/SLA class I negative cells generated by combining both strategies will have extremely low immunogenicity. SLA-HLA typing and [...] recipient ("personalized graft"). Team Prof. Dr. Reinhard Schwinzer Funding SFB-TRR 127 Teilprojekt A1 Collaborations We are working on the project together with Prof. Constanca Figueiredo (MHH, Dept. of

Page

Principal Investigators

Relevance: 94%
 

Carl-Neuberg-Straße 1 30625 Hannover Telefon: +49 511 532-9739 E-Mail: prinz.immo @ mh-hannover.de Sarina Ravens, PhD Medizinische Hochschule Hannover Institut für Immunologie Carl-Neuberg-Straße 1 30625 Hannover [...] Dr. Wolfgang Schamel Albert-Ludwigs-Universität Freiburg Institut für Biologie III Schänzlestraße 1 79104 Freiburg Telefon: +49 761 203-67511 Fax: +49 761 203-97660 E-Mail: wolfgang.schamel @ biologie [...] Benjamin Schusser Technische Universität München Biotechnologie der Reproduktion Liesel-Beckmann-Str. 1/III 85354 Freising Telefon: +49 8161 71-2027 Fax: +49 8161 71-2108 E-Mail: benjamin.schusser @ tum.de

News

974 million euros budgeted for new MHH building

Relevance: 94%
 

catch-up investments at universities under state responsibility" in the amount of 2.1 billion euros. Half of this special fund (1.05 billion euros) is earmarked for the new MHH building, the other half for the [...] "DBHN has examined construction stage 1 on the basis of the construction development plan and has given a positive vote. With the inclusion of construction stage 1 in the financing plan for measures, the [...] MHH new building is well on its way." Space for 562 beds and 24 operating rooms Construction stage 1 comprises the functional areas of the central emergency department, emergency and trauma, heart and

News

Drug combination triples survival time with blood cancer

Relevance: 94%
 

in IDH1-Mutated Acute Myeloid Leukemia" can be found here . The publication on the investigations in the mouse model "Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant [...] been used individually against AML. While the first inhibits a certain gene-modified enzyme called IDH1, which promotes the development of blood cancer cells, the second prevents the cancer cells from growing [...] able to demonstrate this effect in humans who had newly diagnosed AML with gene alterations in the IDH1 enzyme. "We were surprised that the effect was so strong," emphasises the physician. The interaction

Page

Sample preparation

Relevance: 94%
 

higher compared to cell cultivation (Dilution with PBS through sorting: 1nl per sorted cell for 70um nozzle, 3nl for 100um nozzle). 1,5 ml Eppendorf-Cups, 5 ml (12x75 mm) tubes and 15 ml tubes (NOT for sorting [...] resuspend cells that tend to aggregate in EDTA- containing buffer (e.g. PBS, Ca/Mg free, 0,5%BSA with 1-2mM EDTA). It is further recommended to store cells on ice prior to sorting. In samples with low viability [...] the release of DNA. This can be mitigated by supplementation with 10 U/ml DNAse in the presence of 1-5 mM MgCl. Please do not use buffer with EDTA if using DNase! The concentration of cells for sorting

  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • »
Imprint Intranet Contact Privacy Accessibility
The MHH Hospital is a maximum care hospital with a nationwide catchment area. The university teaches medicine, dentistry, biochemistry, biomedicine, midwifery and health sciences. The main research areas are Transplantation and Stem Cell Research / Regenerative Medicine, Infection and Immunology Research, Biomedical Engineering and Implant Research.

   

Information about

Blood donation service MHH-Alumni e.V.

Follow us on

Facebook Instagram YouTube Xing LinkedIn
© 2019 - 2025 Medizinische Hochschule Hannover
Nach oben scrollen